UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000004894
Receipt number R000005684
Scientific Title Effect and Safety of dose-escalating treatment of Imidafenacin for Overactive Bladder : CLSS-modified-Self-Assessment Goal Achievement questionnaire
Date of disclosure of the study information 2011/01/18
Last modified on 2014/01/27 19:56:11

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Effect and Safety of dose-escalating treatment of Imidafenacin for Overactive Bladder : CLSS-modified-Self-Assessment Goal Achievement questionnaire

Acronym

CLSS-modified-SAGE study

Scientific Title

Effect and Safety of dose-escalating treatment of Imidafenacin for Overactive Bladder : CLSS-modified-Self-Assessment Goal Achievement questionnaire

Scientific Title:Acronym

CLSS-modified-SAGE study

Region

Japan


Condition

Condition

Overactive Bladder

Classification by specialty

Urology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To evaluate efficacy and safety of imidafenacin dose escalating treatment for patients with OAB who received treatment with imidafenacin 0.1 mg twice daily and did not have problematic side-effects and not satisfied with treatment. We also survey realistic treatment expectations of outcomes, in terms of addressing individualized treatment
Goals.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

1)CLSS-modified-Self-Assessment Goal Achievement questionnaire : CLSS-modified-SAGA
2)Overactive Bladder Symptom Score : OABSS

Key secondary outcomes

1) IPSS-QOL
2) residual urine volume
3) adverse events and side-effects


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

imidafenacin 0.2mg/day-0.4mg/day bid.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Man and Woman over 20years who had OAB symptom, >=8voids/day, urgency and would like to have a treatment for OAB symptom.

Key exclusion criteria

1)Polyuria (daily urine volume >=3000mL)
2)Residual urine >=100mL
3)Suspect of prostate cancer
4)Indwelling catheter or self intermittent urinary catherization
5)The shift work and patients with irregular lifestyle
6)Bladder training conducted over the past 10 days
7)Active urinary tract infection
8)Having been given hormones or 5 alpha-reductase inhibitor within the past six months
9)Contraindication to imidafenacin (Primary angle-closure glaucoma , urinary retention , Obstructive intestinal disease, paralytic ileus, gastrointerstinal atony , myastania gravis )
10)Judged as being unsuitable for the trial by the researcher.

Target sample size

500


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Masato Fujisawa

Organization

Kobe University Graduate School of Medicine

Division name

Urology

Zip code


Address

7-5-1 Kusunoki-Cho, Chuo-Ku, Kobe, 650-0017 Japan.

TEL

078-382-6155

Email

urokobe@med.kobe-u.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Akihiro Yanagiuchi

Organization

Kobe University Graduate School of Medicine

Division name

urology

Zip code


Address

7-5-1 Kusunoki-Cho, Chuo-Ku, Kobe, 650-0017 Japan.

TEL

078-382-6155

Homepage URL


Email

urokobe@med.kobe-u.ac.jp


Sponsor or person

Institute

Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan

Institute

Department

Personal name



Funding Source

Organization

none

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2011 Year 01 Month 18 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2011 Year 01 Month 01 Day

Date of IRB


Anticipated trial start date

2011 Year 04 Month 01 Day

Last follow-up date

2013 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2011 Year 01 Month 18 Day

Last modified on

2014 Year 01 Month 27 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000005684


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name